SUSTAINED EFFICACY OF BIMEKIZUMAB TREATMENT ASSESSED USING COMPOSITE DISEASE ACTIVITY MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROMTHE PHASE 3 BE COMPLETE STUDY AND ITS OPEN LABEL EXTENSION UP TO 1 YEAR

被引：0

作者：

Coates, L. ^{[1
,2
]}

Landewe, R. B. M. ^{[3
]}

Mcinnes, I. ^{[4
]}

Ritchlin, C. T. ^{[5
]}

Gottlieb, A. B. ^{[6
]}

Orbai, A. M. ^{[7
]}

Warren, R. B. ^{[8
]}

Ink, B. ^{[9
]}

Bajracharya, R.

Coarse, J. ^{[10
]}

Merola, J. F. ^{[11
]}

机构：

[1] Univ Oxford, Oxford Univ Hosp NHS Trust, Nuffield Dept Orthopaed, Rheumatol & Musculoskeletal Dis, Oxford, England

[2] Oxford Biomed Res Ctr, Oxford, England

[3] Amsterdam & Zuyderland MC, Amsterdam Rheumatol Clin Immunol Ctr, Heerlen, Netherlands

[4] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow, Scotland

[5] Univ Rochester, Allergy Immunol Rheumatol Div, Med Sch, Rochester, NY USA

[6] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA

[7] Johns Hopkins Univ, Div Rheumatol, Sch Med, Baltimore, MD USA

[8] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester NIHR Biomed Res Ctr, Manchester, England

[9] UCB Pharma, Slough, Berks, England

[10] UCB Pharma, Morrisville, NY USA

[11] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷

关键词：

Clinical trials; Psoriatic arthritis;

D O I：

10.1136/annrheumdis-2023-eular.1671

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

AB1099

引用

页码：1775 / 1776

页数：2

共 32 条

[21] Efficacy and safety of baricitinib in patients with active rheumatoid arthritis and inadequate response to tumour necrosis factor inhibitors: 24-week phase 3 RA-BEACON study results
Zamani, O.
Combe, B.
Tony, H. P.
Sanchez Burson, J.
Tahir, H.
Ostergaard, M.
Augendre-Ferrante, B.
Beselin, A.
Larsson, E.
Casillas, M.
Smolen, J.
SWISS MEDICAL WEEKLY, 2016, 146 : 3S - 3S
[22] Sustained Improvement in Physical Function, Disease Impact and Health-Related Quality of Life in Patients with Psoriatic Arthritis Treated with Bimekizumab: 3-Year Results from a Phase 2b Open-Label Extension Study
Gossec, Laure
Asahina, Akihiko
Gottlieb, Alice
Coates, Laura
Ink, Barbara
Assudani, Deepak
Coarse, Jason
Hellot, Scarlett
Eells, Jason
Mease, Philip
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2814 - 2818
[23] Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: 16 week results of a phase 3 randomised, double-blind, placebo-controlled trial in patients with prior inadequate response or intolerance to 1 or 2 tumour necrosis factor inhibitors
Gonzalez, C.
Aletaha, D.
Nassab, M. H.
Bello, N.
Pum, G.
Bradley, A.
Liu-Leage, S.
SWISS MEDICAL WEEKLY, 2019, : 18S - 18S
[24] Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD- Naive or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies
Husni, M. Elaine
Mease, Philip J.
Merola, Joseph
Behrens, Frank
Favalli, Ennio G.
McGonagle, Dennis
Tillett, William R.
Tsuji, Shigeyoshi
Ink, Barbara
Bajracharya, Rajan
Lambert, Jeremy
Coarse, Jason
Gossec, Laure
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1035 - 1038
[25] Sustained Response in a Phase 3 Study of Sarilumab Plus Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
Fleischmann, Roy
St. John, Greg
Kimura, Toshio
Iglesias-Rodriguez, Melitza
Rosner, Itzhak
Burmester, Gerd R.
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[26] SUSTAINED RESPONSE IN A PHASE 3 STUDY OF SARILUMAB PLUS NONBIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN PATIENTS WITH ACTIVE, MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO TUMOR NECROSIS FACTOR INHIBITORS
Fleischmann, R.
St John, G.
Kimura, T.
Iglesias-Rodriguez, M.
van Hoogstraten, H.
Rosner, I
Burmester, G. R.
INTERNAL MEDICINE JOURNAL, 2018, 48 : 21 - 22
[27] Bimekizumab achieved sustained improvements in efficacy outcomes in patients with axial spondyloarthritis, regardless of prior tumour necrosis factor inhibitor treatment: week 52 pooled results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2
Magrey, Marina
Van de Sande, Marleen
Breban, Maxime
Van den Bosch, Filip
Fleurinck, Carmen
Massow, Ute
de Peyrecave, Natasha
Vaux, Thomas
Baraliakos, Xenofon
Marzo-Ortega, Helena
RHEUMATOLOGY, 2024, 63
[28] BIMEKIZUMAB ACHIEVED SUSTAINED IMPROVEMENTS IN EFFICACY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, REGARDLESS OF PRIOR TUMOUR NECROSIS FACTOR INHIBITOR TREATMENT: WEEK 52 POOLED RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
Magrey, Marina
Van de Sande, Marleen
Breban, Maxime
Van den Bosch, Filip
Fleurinck, Carmen
Massow, Ute
de Peyrecave, Natasha
Vaux, Thomas
Baraliakos, Xenofon
Marzo-Ortega, Helena
RHEUMATOLOGY, 2024, 63 : I110 - I111
[29] SUSTAINED IMPROVEMENTS IN PHYSICAL FUNCTION, QUALITY OF LIFE, AND WORK PRODUCTIVITY WITH IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR-INHIBITORS: 3-YEAR RESULTS FROM SPIRIT-P2 TRIAL
Orbai, A. M.
Gratacos-Masmitja, J.
Dokoupilova, E.
Combe, B.
Constantin, A.
Gellett, A. M.
Sprabery, A. T.
Birt, J.
Geneus, V.
Nash, P.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1705 - 1706
[30] Guselkumab Provides Clinically Meaningful Improvents in Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Who Are Inadequate Responders to Tumour Necrosis Factor Inhibitors: Results Through One Year of a Phase 3b, Randomized, Controlled Study (COSMOS)
Gossec, Laure
Baraliakos, Xenofon
Galloway, James
Erik, Lars
Oke, Vilija
Sfikakis, Petros
Rampakakis, Emmanouil
Sharaf, Mohamed
Lavie, Frederic
McInnes, Iain
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2807 - 2809

← 1 2 3 4 →